Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128271 | 0.82 | KDM4E (0.36) | CYP2D6CYP2C19ALDH1A1SYK | |
| SCHEMBL838330 | 0.78 | CYP2D6 (0.37) | CYP2D6CYP2C19ALDH1A1MAPTPTGS1 | |
| SCHEMBL8225884 | 0.78 | SYK (0.32) | SYK | |
| SCHEMBL8255995 | 0.78 | SYK (0.32) | SYK | |
| SCHEMBL8225897 | 0.78 | SYK (0.32) | SYK | |
| SCHEMBL1025812 | 0.78 | CYP2D6 (0.42) | CYP2D6CYP2C19 | |
| SCHEMBL17768026 | 0.77 | CYP2D6 (0.44) | CYP2D6CYP2C19SYK | |
| SCHEMBL4683204 | 0.77 | ALDH1A1 (0.43) | ALDH1A1MAPTPTGS1 | |
| Hydrochloric Acid SCHEMBL4854705 | 0.77 | CYP2D6 (0.41) | CYP2D6CYP2C19 | |
| SCHEMBL2723468 | 0.75 | MEN1 (0.46) | CYP2D6SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3828163-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | AUTOTAC INC (KR) | 2026-05-20 | — | — | EP | disclosed |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2025-09-30 | — | — | US | disclosed |
| US-12145913-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-115215807-A | Inhibition of OLIG2 activity | 科泰纳制药公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-115087660-A | Synthetic triterpenoids with nitrogen-based substituents at C-17 and methods of use thereof | 里亚塔医药公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114728970-A | Optical proximity analysis of protein-protein interactions in cells | 芝加哥大学 | 2022-07-08 | — | — | CN | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3922635-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20210163399-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME | PROTECH CO., LTD. (KR) | 2021-06-03 | — | — | US | disclosed |
| US-20030069445-A1 | Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide | AUDIA JAMES E (US) | 2003-04-10 | — | — | US | disclosed |
| US-6486350-B1 | Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide | ELAN PHARMACEUTICALS INC. | 2002-11-26 | — | — | US | disclosed |
| WO-2002044147-A1 | PROCESS FOR PREPARING DISTAMYCIN DERIVATIVES | PHARMACIA ITALIA S.P.A. (IT) | 2002-06-06 | — | — | WO | disclosed |
| EP-0934065-A4 | PHARMACEUTICAL COMPOUNDS | LILLY CO ELI (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6121433-A | FOR DIAGNOSTIC, RESEARCH AND THERAPEUTIC USE; MIMIC OR MODULATE PROTEINS, ENZYMES, NUCLEIC ACIDS AND LIPIDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0746326-A4 | OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0934065-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998008505-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0746326-A1 | OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995018623-A1 | OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | CYP2D6 4807/4885CYP2C19 4880/4885ALDH1A1 1478/4885 |
| US-20210163399-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME | SQSTM1, ATG7, BECN1 | CYP2D6 4487/4885CYP2C19 4801/4885ALDH1A1 4667/4885 |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | CYP2D6 4452/4885CYP2C19 4828/4885ALDH1A1 4677/4885 |
| US-12145913-B2 | Inhibition of Olig2 activity | POU2F2, POU2F1, PLP2 | CYP2D6 4624/4885CYP2C19 4574/4885ALDH1A1 1823/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | CYP2D6 4787/4885CYP2C19 4860/4885ALDH1A1 1801/4885 |
| US-20030069445-A1 | Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide | APP, IAPP, BACE1 | CYP2D6 4597/4885CYP2C19 4662/4885ALDH1A1 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.